Advances in Brief

Targeting Oncolytic Adenoviral Agents to the Epidermal Growth Factor Pathway with a Secretory Fusion Molecule

Akseli Hemminki, Igor Dmitriev, Bin Liu, Renee A. Desmond, Ramon Alemany, and David T. Curiel

Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center [A. H., I. D., B. L., R. A., D. T. C.], and Comprehensive Cancer Center Biostatistics Unit [R. A. D.], University of Alabama at Birmingham, Birmingham, Alabama 35294-3300

Abstract

Cancer gene therapy with conditionally replicating adenoviruses is a powerful way of overcoming low tumor transduction. However, one of the main remaining obstacles is the highly variable level of the coxsackie-adenovirus receptor expression on human primary cancers. In contrast, the epidermal growth factor receptor (EGFR) is overexpressed in various tumor types, and its expression correlates with metastatic behavior and poor prognosis. We constructed an adenovirus expressing a secretory adaptor capable of retargeting adenovirus to EGFR, resulting in a more than 150-fold increase in gene transfer. A replication-competent dual-virus system secreting the adaptor displayed increased oncolytic potency in vitro and therapeutic gain in vivo. This approach could translate into increased efficacy and specificity in the treatment of EGFR overexpressing human cancers.

Introduction

CRADs are a promising and novel way of overcoming low tumor transduction, which is the main obstacle preventing effective gene transfer and therapeutic effect in clinical applications of cancer gene therapy (1). However, one of the main reasons why the unparalleled transduction efficacy of Ads has not translated into similar results in humans is the variable level of the CAR on primary cancers (2–9) in vivo. CAR is ubiquitously expressed on normal epithelial tissues and is the main receptor mediating binding of the most commonly used Ad serotypes 2 and 5. Expression of CAR may be the major factor determining the rate of transduction (4, 6, 9–11). Importantly, recent evidence (11) suggests that CAR expression may inversely correlate with the malignant potential of tumors, resulting in low infectivity of highly aggressive tumors. In contrast to the expression profile of CAR, EGFR, the prototype of cancer-associated receptors, is commonly overexpressed in many if not most carcinomas with correlation to metastatic behavior and poor prognosis (12). A powerful approach for increasing tumor transduction could be combining the tissue-penetrating capability of CRADs with the transductional control provided by retargeting moieties. In support of this hypothesis, an artificial receptor system has been used to demonstrate that the effect of Ad dispersion and subsequent oncolysis critically depends on receptor expression (13). We have constructed a novel virus that mediates secretion of a fusion molecule consisting of the extracellular domain of CAR and EGF. We then explored the capability of the sCAR-EGF to retarget Ad to EGFR. Finally, we demonstrated that infection of cancer cells with a sCAR-EGF-retargeted replication-competent dual-virus system resulted in increased oncolysis in vitro and a therapeutic benefit in vivo.

Materials and Methods

Viruses. For construction of AdsCAR-EGF, a replication-deficient Ad with sCAR-EGF in E1, the gene coding for sCAR-EGF was cloned from pBsEgE1 (14) into pShuttle-CMV (Quantum, Montreal, Quebec, Canada). Homologous recombination with pAdEasy-1 (Quantum) was performed in Escherichia coli, followed by confirmation of structure with EcoRV and Puc1 digestions, PCR, and sequencing of the transgene (data not shown). The viral genome was transduced into 293 cells for plaque purification, followed by cesium chloride purification and standard titering with OD260 and plaque assay. Resulting titers were 3.8 × 10^{10} VP/ml and 1.0 × 10^{10} plaque-forming units/ml, ratio = 38.4 VP/plaque-forming unit. Large-scale preparations of AdCMVLuc (a nonreplicating Ad-expressing luciferase; courtesy of Dr. Robert Gerard, Texas Southwestern Medical Center, Dallas, TX), AdsCAR6H (a nonreplicating Ad-mediating secretion of sCAR6H), and ΔΔ24 (an Ad with a 24-bp deletion in E1A, allowing selective replication in cells mutant in the Rh-p16 pathway; Ref. 15) were performed with standard methods on 293 cells (or A549 cells for ΔΔ24).

CRAdsCAR-EGF denotes a replication-competent, sCAR-EGF-secreting dual-virus system consisting of equal VP of AdsCAR-EGF and ΔΔ24 mixed immediately before administration to cells. CRAdCMVLuc is the respective combination of ΔΔ24 and AdCMVLuc. ΔΔ24 has been characterized previously (15). Validating the dual-virus strategy, it has been demonstrated that transcomplementation of E1 proteins from a plasmid or replication-competent virus results in replication of E1-deleted viruses present in the same cell (9, 16–18).

Cell Lines. 293 cells were purchased from Microbix (Toronto, Ontario, Canada). A549 (lung cancer), HeLa (cervical cancer), U118 (glioma), A431 (squamous cell skin cancer), BT474, and MB-453 (breast cancer) were obtained from the American Type Culture Collection (Rockville, MD), and SKOV3.ip1 cells (ovarian cancer) are from Dr. Janet Price (M. D. Anderson Cancer Center, Houston, TX). Cell lines were propagated in the recommended conditions.

Protein Detection. HeLa cells were infected overnight with 50 VP/cell, and BT474 and MB453 cells were infected with 500 VP/cell of AdsCAR-EGF, AdsCAR6H, and AdCMVLuc. Supernatants were collected at 48 h, and cellular debris was removed by centrifugation. Dilutions in a volume of 300 μl were transferred onto a nitrocellulose membrane using the Bio-Dot apparatus (Bio-Rad). BSA (3%) was used for blocking, followed by detection with a 1:5000 polyclonal mouse anti-CAR antibody (14) and 1:2000 goat antimouse alkaline phosphatase (Sigma Chemical Co., St. Louis, MO) in 3% BSA. Western blot analysis on the supernatants was performed with standard methodology in a 12% two-phase gel, and proteins were detected as above. Baculovirus-expressed and -purified sCAR-EGF and sCAR6H (14) were used as controls.

Received 5/2/01; accepted 7/16/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by the Damon Runyon-Walter Winchell Foundation, the Sigrid Juselius Foundation, the Emil Aaltonen Foundation, the Maud Kuistila Foundation, and Comprehensive Cancer Center Biostatistics Unit [R. A. D.], University of Alabama at Birmingham, Birmingham, Alabama 35294-3300.
Results

Infection of Cells with AdsCAR-EGF Results in Secretion of sCAR-EGF. Initially, infection of high EGFR HeLa cells (23) with AdsCAR-EGF produced no evidence of secretion, whereas sCAR6H was secreted (Fig. 1). With low EGFR-expressing cells MB453 and BT474 (14, 24), secretion of sCAR-EGF was detected. The amount of protein was estimated at 110 ng/ml (75-cm² flask; 12 ml of medium). Western blot confirmed secretion (Fig. 1B). The altered migration rate of the protein in comparison with baculovirus-expressed sCAR-EGF perhaps resulted from altered charge caused by different glycosylation by insect cells. A preliminary investigation on sCAR-EGF toxicity was performed by infecting SKOV3.ip1 and A431 cells with various amounts of AdsCAR-EGF and AdsCAR6H without significant differences in cell viability (data not shown).

Secreted sCAR-EGF Mediates Retargeting of Ad to EGFR. Aliquots of supernatant from AdsCAR-EGF-infected BT474 cells were incubated with AdCMVLuc. The virus-supernatant mix was used for infection of SKOV3.ip1, U118, and A431 cells, which display moderate (SKOV3.ip1 and U118) to high (A431) EGFR expression and moderate (A431) to low (SKOV3.ip1 and U118) CAR expression (4, 14). A supernatant dose-dependent increase in luciferase expression was seen, with the highest readings 17.1-, 20.2-, and 158-fold higher than without retargeting for SKOV3.ip1, U118, and A431 cells, respectively (curves with triangles in Fig. 2).

With the highest amounts of supernatant from AdsCAR6H-infected cells, luciferase expression was reduced to 73%, 48%, and 65% (on SKOV3.ip1, U118, and A431, respectively) of the highest values for the series (curves with squares in Fig. 2). sCAR6H binds to Ad fiber but does not mediate binding to EGFR, thus modeling blockage of CAR-binding with sCAR-EGF.

Retargeting Replication-competent Ad to EGFR Results in Increased Cell Killing in Vitro. To validate Δ24 replication in SKOV3.ip1 cells, infections were performed at 0, 0.01, 0.1, or 1 VP/cell, and aliquots of supernatant (from BT474 cells infected with

Fig. 1. Secretion of sCAR-EGF from human cancer cells infected with AdsCAR-EGF. A, supernatant from MB453 and BT474 (both low EGFR breast cancer lines) cells infected with AdsCAR6H (codes for human CAR ectodomain, positive control), AdsCAR-EGF, or AdCMVLuc (negative control) was centrifuged and then transferred onto a membrane. Arrow, the signal for sCAR-EGF. When compared with known amounts of sCAR-EGF (lowest row), the amount of secretion could be estimated at 110 ng/ml. B, Western blot suggested that the sCAR-EGF secreted from BT474 and MB453 cells (Lanes 1–2) was close in size to baculovirus-expressed sCAR-EGF (Lane 3). High EGFR HeLa cells (Lane 3) did not show evidence of sCAR-EGF secretion, but the positive control sCAR6H was secreted (Lane 9). --, supernatants collected from cells infected with AdCMVLuc (Lanes 4 and 7). These serve as negative controls. +, the positive controls, including Lane 8, which has supernatant from BT474 cells infected with AdsCAR6H. sCAR-EGF and sCAR6H (Lanes 5–6) are purified baculovirus-expressed proteins.
AdsCAR-EGF or AdCMVLuc) were added daily. At 20 days, cell killing and partial loss of monolayer was seen only with cells that had been infected with 1 VP/cell and subjected to AdsCAR-EGF/BT474 supernatant (data not shown).

To study the effect of continuous sCAR-EGF secretion on the oncolytic potential of CRAds, we infected SKOV3.ip1 and A431 cells with the CRAdsCAR-EGF and CRAdCMVLuc dual-virus systems. On both cell lines, infection with CRAdsCAR-EGF resulted in cell killing with one to two orders of magnitude less virus than with CRAdCMVLuc (Fig. 3).

Targeting Replicative Ad to EGFR Results in a Therapeutic Advantage in Vivo. Various proportions of infected and uninfected A431 cells were mixed and injected s.c. (Fig. 4A). One percent of infected cells was sufficient to inhibit tumor growth, and 5% or more resulted in healing of tumors. None of the mice showed signs of illness or distress, suggesting that the secretion of sCAR-EGF did not cause overt toxicity.

To evaluate sCAR-EGF retargeting in vivo, CRAdsCAR-EGF or CRAdCMVLuc were administered with a single intratumoral injection into established A431 tumors (Fig. 4, B–C). The change-point test (20) revealed that the tumor growth pattern changed at 13 days for $10^9$ VP CRAdsCAR-EGF ($P = 0.0045$), 21 days for $10^9$ VP CRAdCMVLuc ($P = 0.0012$), 17 days for $10^8$ VP CRAdsCAR-EGF ($P = 0.0026$), and 25 days for $10^8$ VP CRAdCMVLuc ($P = 0.0011$), i.e., 8 days earlier for CRAdsCAR-EGF with both doses.

The change-point test and the test of fixed effects (22) showed that there was a significant correlation between observations of tumor size and time ($P < 0.0001$ for all of the groups). A polynomial equation was fit for each group, thereby creating a mathematical model for each growth pattern ("modeled" in Fig. 4). The mixed model (22) was used...
to allow for the curvature of the plots, which was caused by the opposite effects of oncolysis and cell division. For the mice that received injections with $10^9$ VP, groups were significantly different from day 29 onwards ($P < 0.05$; Fig. 4B). When $10^8$ VP was used (Fig. 4C), the differences were significant from day 25 onwards ($P = 0.0066$ and 0.0003 on days 25 and 29, respectively, and $< 0.0001$ on days 33–35).

**Discussion**

In this study, we report construction of the first human Ad secreting a paracrine adaptor molecule. Secretion of sCAR-EGF was demonstrated with low EGFR cells (Lanes 1 and 2, Fig. 1), but not with high EGFR HeLa cells (23). In contrast, secretion was detected when HeLa cells were infected with AdsCAR6H, which codes for ectodomain of CAR but not EGF (Lane 9, Fig. 1B). EGF exhibits high affinity binding to EGFR, which leads to rapid internalization but no recycling of the receptor-ligand complex (12). Thus, perhaps secreted sCAR-EGF also internalizes. Alternatively, binding without internalization would also limit the amount of sCAR-EGF in the supernatant.

Supporting the capacity of sCAR-EGF to mediate binding and subsequent internalization of Ad, supernatant containing the fusion molecule resulted in dose-dependent increases in marker gene expression (Fig. 2). The shape of the curves suggests that the upper limit of retargeting potential was not reached. In an *in vitro* system, it is difficult to assess the capability of a secreted fusion molecule to block fiber-CAR interaction, because in the absence of CAR binding, uptake of Ad into cells can also occur via alternative mechanisms (10). However, we observed up to 52% reduction in luciferase expression with sCAR6H, which could translate into partial blocking of CAR-mediated internalization (into normal cells) by sCAR-EGF *in vivo*, but additional studies are needed.

We used a dual-virus system (CRAAdSCAR-EGF) to evaluate the combination of oncolysis and EGFR targeting and saw dramatically increased killing of cells relatively low in CAR but high in EGFR expression, a combination commonly seen with primary cancer cells (Fig. 3). *In vitro*, the isogenic control virus (CRAAdCMVLuc) is expected to enter cells even if they are low in CAR (10). The observed difference in oncolysis may result from more rapid internalization of the retargeted virus because of a higher number of receptors. In a living organism, extracellular viruses are at risk for neutralization by immune defenses or being swept away into organs responsible for Ad clearance. Thus, the advantage of rapid binding and internalization could be more pronounced.

s.c. xenografts are a stringent model for testing an oncolytic effect, because viral replication is balanced against rapid tumor growth. Here, we demonstrated significantly improved therapeutic efficacy of CRAAdSCAR-EGF in comparison with the isogenic control not secreting sCAR-EGF (Fig. 4).

No signs of sCAR-EGF-causing toxicity were evident when cells were infected with AdsCAR-EGF in comparison with AdsCAR6H. When sCAR-EGF was added daily to SKOV3.ip1 cells infected with a CRAD, no evidence of toxicity to cells was seen. Moreover, obvious signs of toxicity were absent in mice whose xenografts were infected with CRAAdSCAR-EGF. Additional studies will show whether the adaptor molecule has an effect of cell growth or whether there is toxicity *in vivo*. Also, it remains to be seen whether sCAR-EGF mediates Ad internalization via the EGFR pathway or merely substitutes for CAR in binding Ad for the native entry mechanism via penton base arginine-glycine-aspartic acid and cellular integrins.

This is the first report of a retargeting molecule secretory from human cells, but this strategy could be feasible with various high-affinity, cancer-specific ligands. Because rapid screening methods allow recognition of large numbers of cancer-specific features, unlimited possibilities for retargeting with secretory-targeting moieties
may soon be available. The dual-virus system used here provides a useful model for rendering AdsCAR-EGF replicative and investigating the combination of oncolysis and retargeting, but efficacy could be improved when sCAR-EGF is genetically incorporated into a CRAD.

In conclusion, we show that retargeting of replicating Ad to a receptor overexpressed in cancers is a powerful way of increasing tumor transduction and allows overcoming the lack of the primary Ad receptor. Clinical translation of this approach may be effective in treatment of a variety of human cancers that overexpress EGFR.

References


Targeting Oncolytic Adenoviral Agents to the Epidermal Growth Factor Pathway with a Secretory Fusion Molecule

Akseli Hemminki, Igor Dmitriev, Bin Liu, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/17/6377

Cited articles
This article cites 21 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/17/6377.full.html#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
/content/61/17/6377.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.